A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer

BACKGROUND: The prognosis of patients under existing neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy requires improvement. Whereas programmed cell death 1 (PD-1) inhibitors have shown promising response in advanced esophageal cancer, they have not been used in the perioperative treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Huiru, Liu, Minling, Li, Xueying, Li, Tingwei, Huang, Wensheng, Liao, Jiehao, Li, Yun, Fang, Shuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414113/
https://www.ncbi.nlm.nih.gov/pubmed/36008813
http://dx.doi.org/10.1186/s12957-022-02732-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414113/
https://www.ncbi.nlm.nih.gov/pubmed/36008813
http://dx.doi.org/10.1186/s12957-022-02732-w

Ejemplares similares